본문 바로가기
KERD
논문KCI 등재

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region

Woochang Lee|Teng-Yu Lee|Ming-Lung Yu|Tawesak Tanwandee|Tian Yang|김도영|Bao Nguyen Toan|Chee-Kiat Tan|Irsan Hasan|Lyana Setiawan|Namiki Izumi|Nguyen Nguyen Huyen|Pierce Kah-Hoe Chow|Rosmawati Mohamed|Stephen Lam Chan|Thi Thanh Nguyen Hai|Henry Lik Yuen Chan
대한간학회 (The korean Association for the Study of the Liver)|2023.04|Clinical and Molecular Hepatology|제29권 제2호|pp. 277-292

2

조회

0

다운로드

5

인용

0

참고문헌

키워드

ConsensusBiomarkersCarcinomahepatocellularAlpha-fetoproteinPIVKA-II

초록

Even though the combined use of ultrasound (US) and alpha-fetoprotein (AFP) is recommended for the surveillance of hepatocellular carcinoma (HCC), the utilization of AFP has its challenges, including accuracy dependent on its cut-off levels, degree of liver necroinflammation, and etiology of liver disease. Though various studies have demonstrated the utility of protein induced by vitamin K absence II (PIVKA-II) in surveillance, treatment monitoring, and predicting recurrence, it is still not recommended as a routine biomarker test. A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and treatment monitoring of HCC, based on six predetermined statements. The experts agreed that PIVKA-II was valuable in the detection of HCC in AFP-negative patients, and could potentially benefit detection of early HCC in combination with AFP. PIVKA-II is clinically useful for monitoring curative and intra-arterial locoregional treatments, outcomes, and recurrence, and could potentially predict microvascular invasion risk and facilitate patient selection for liver transplant. However, combining PIVKA-II with US and AFP for HCC surveillance, including small HCC, still requires more evidence, whilst its role in detecting AFP-negative HCC will potentially increase as more patients are treated for hepatitis-related HCC. PIVKA-II in combination with AFP and US has a clinical role in the Asia-Pacific region for surveillance. However, implementation of PIVKA-II in the region will have some challenges, such as requiring standardization of cut-off values, its cost-effectiveness and improving awareness among healthcare providers.

Abstract

Even though the combined use of ultrasound (US) and alpha-fetoprotein (AFP) is recommended for the surveillance of hepatocellular carcinoma (HCC), the utilization of AFP has its challenges, including accuracy dependent on its cut-off levels, degree of liver necroinflammation, and etiology of liver disease. Though various studies have demonstrated the utility of protein induced by vitamin K absence II (PIVKA-II) in surveillance, treatment monitoring, and predicting recurrence, it is still not recommended as a routine biomarker test. A panel of 17 experts from Asia-Pacific, gathered to discuss and reach a consensus on the clinical usefulness and value of PIVKA-II for the surveillance and treatment monitoring of HCC, based on six predetermined statements. The experts agreed that PIVKA-II was valuable in the detection of HCC in AFP-negative patients, and could potentially benefit detection of early HCC in combination with AFP. PIVKA-II is clinically useful for monitoring curative and intra-arterial locoregional treatments, outcomes, and recurrence, and could potentially predict microvascular invasion risk and facilitate patient selection for liver transplant. However, combining PIVKA-II with US and AFP for HCC surveillance, including small HCC, still requires more evidence, whilst its role in detecting AFP-negative HCC will potentially increase as more patients are treated for hepatitis-related HCC. PIVKA-II in combination with AFP and US has a clinical role in the Asia-Pacific region for surveillance. However, implementation of PIVKA-II in the region will have some challenges, such as requiring standardization of cut-off values, its cost-effectiveness and improving awareness among healthcare providers.

참고문헌 (63)

  1. Rawla P, "Update in global trends and aetiology of hepatocellular carcinoma", Contemp Oncol(Pozn), 22, pp.141~150 (2018)
  2. Tang A, "Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis", Abdom Radiol(NY), 43, pp.13~25 (2018)
  3. Yang JD, "A global view of hepatocellular carcinoma : trends, risk, prevention and management", Nat Rev Gastroenterol Hepatol, 16, pp.589~604 (2019)
  4. Omata M, "AsiaPacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
  5. Galle PR, "Biology and significance of alpha-fetoprotein in hepatocellular carcinoma", Liver Int, 39, pp.2214~2229 (2019)
  6. Lou J, "Biomarkers for hepatocellular carcinoma", Biomark Cancer, 9, pp.1~9 (2017)
  7. Zhang J, "The threshold of alpha-fetoprotein(AFP)for the diagnosis of hepatocellular carcinoma : a systematic review and meta-analysis", PLoS One, 15, pp.e0228857~ (2020)
  8. Weitz IC, "Des-gamma-carboxy(abnormal)prothrombin and hepatocellular carcinoma : a critical review", Hepatology, 18, pp.990~997 (1993)
  9. Seo SI, "Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virusassociated hepatocellular carcinoma", World J Gastroenterol, 21, pp.3928~3935 (2015)
  10. Guan MC, "Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease : a multicenter analysis", Hepatobiliary Pancreat Dis Int, 21, pp.559~568 (2022)
  11. Chen H, "Combining desgamma-carboxyprothrombin and alpha-fetoprotein for hepatocellular carcinoma diagnosing : an update meta-analysis and validation study", Oncotarget, 8, pp.90390~90401 (2017)
  12. Nakamura S, "Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size", Am J Gastroenterol, 101, pp.2038~2043 (2006)
  13. Lok AS, "Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma", Gastroenterology, 138, pp.493~502 (2010)
  14. Ji J, "Diagnostic evaluation of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatitis B virus-related hepatocellular carcinoma in china : a large-scale, multicentre study", PLoS One, 11, pp.e0153227~ (2016)
  15. Pepe MS, "Phases of biomarker development for early detection of cancer", J Natl Cancer Inst, 93, pp.1054~1061 (2001)
  16. Singal AG, "International Liver Cancer Association(ILCA)white paper on biomarker development for hepatocellular carcinoma", Gastroenterology, 160, pp.2572~2584 (2021)
  17. Di Bisceglie AM, "Prolonged therapy of advanced chronic hepatitis c with low-dose peginterferon", N Engl J Med, 359, pp.2429~2441 (2008)
  18. Choi J, "Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma", Hepatology, 69, pp.1983~1994 (2019)
  19. Singal AG, "GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis", Hepatology, 75, pp.541~549 (2022)
  20. Tayob N, "The Performance of AFP, AFP-3, DCP as biomarkers for detection of hepatocellular carcinoma(HCC) : a phase 3 biomarker study in the United States", Clin Gastroenterol Hepatol, 21, pp.415~423 (2023)
  21. De J, "A systematic review of des-γ-carboxy prothrombin for the diagnosis of primary hepatocellular carcinoma", Medicine(Baltimore), 95, pp.e3448~ (2016)
  22. Caviglia GP, "Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection : a meta-analysis", Scand J Gastroenterol, 53, pp.734~740 (2018)
  23. Feng H, "PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma", BMC Cancer, 21, pp.401~ (2021)
  24. Ricco G, "Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers", Cancer Biomark, 21, pp.603~612 (2018)
  25. Yu R, "Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data", BMC Cancer, 17, pp.608~ (2017)
  26. Xing H, "Protein induced by vitamin K absence or antagonist-II versus alphafetoprotein in the diagnosis of hepatocellular carcinoma : a systematic review with meta-analysis", Hepatobiliary Pancreat Dis Int, 17, pp.487~495 (2018)
  27. ateishi R, "Diagnostic accuracy of tumor markers for hepatocellular carcinoma : a systematic review", Hepatol Int, 2, pp.17~30 (2008)
  28. Ibrahim A. Hanouneh, "Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?", Clinical and Molecular Hepatology, 25(3), pp.264~269 (2019), 대한간학회
  29. Marrero JA, "Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma", Gastroenterology, 137, pp.110~118 (2009)
  30. Poté N, "Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion", J Hepatol, 62, pp.848~854 (2015)
  31. Wang T, "New blood biomarkers for the diagnosis of AFP-negative hepatocellular carcinoma", Front Oncol, 10, pp.1316~ (2020)
  32. Farinati F, "Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma : both or neither?", Am J Gastroenterol, 101, pp.524~532 (2006)
  33. Tokushige K, "Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease : multicenter survey", J Gastroenterol, 51, pp.586~596 (2016)
  34. Liu Z, "Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoproteinnegative hepatitis B virus-related hepatocellular carcinoma", J Int Med Res, 48, pp.300060520902575~ (2020)
  35. Wang X, "Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II(PIVKA-II)for early stage HBV related hepatocellular carcinoma", Infect Agent Cancer, 12, pp.47~ (2017)
  36. Xu F, "The diagnostic value of serum PIVKA-II alone or in combination with AFP in Chinese hepatocellular carcinoma patients", Dis Markes, 2021, pp.8868370~ (2021)
  37. Li T, "PIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma", Infect Agent Cancer, 14, pp.13~ (2019)
  38. Kawaguchi T, "Challenges and prospects in prediction and treatment for hepatocellular carcinoma with microvascular invasion", Hepatobiliary Surg Nutr, 8, pp.651~654 (2019)
  39. Ma XL, "Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virusassociated hepatocellular carcinoma", Oncol Lett, 15, pp.8396~8404 (2018)
  40. Masuda T, "Predictive factors of pathological vascular invasion in hepatocellular carcinoma within 3 cm and three nodules without radiological vascular invasion", Hepatol Res, 46, pp.985~991 (2016)
  41. Yamashita YI, "Microvascular invasion of single small hepatocellular carcinoma ≤3 cm : predictors and optimal treatments", Ann Gastroenterol Surg, 2, pp.197~203 (2018)
  42. Zhang D, "Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation : a systematic review and meta-analysis", Int J Biol Markers, 33, pp.266~274 (2018)
  43. Yu Z, "Comparison of ultrasound guided versus CT guided radiofrequency ablation on liver function, serum PIVKA-II, AFP levels and recurrence in patients with primary hepatocellular carcinoma", Am J Transl Res, 13, pp.6881~6888 (2021)
  44. Imai K, "Microvascular invasion in small-sized hepatocellular carcinoma : significance for outcomes following hepatectomy and radiofrequency ablation", Anticancer Res, 38, pp.1053~1060 (2018)
  45. Chon YE, "Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma", Int J Cancer, 131, pp.2332~2341 (2012)
  46. Park H, "Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma", Biomed Res Int, 2013, pp.310427~ (2013)
  47. Hong YM, "Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma", Tumour Biol, 39, pp.1010428317720863~ (2017)
  48. Kim DY, "PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection", Oncology, 72(Suppl 1), pp.52~57 (2007)
  49. Wang BL, "Elevated PIVKAII is associated with early recurrence and poor prognosis in BCLC 0-A hepatocellular carcinomas", Asian Pac J Cancer Prev, 15, pp.6673~6678 (2014)
  50. Gao F, "Predictive value of tumor markers in patients with recurrent hepatocellular carcinoma in different vascular invasion pattern", Hepatobiliary Pancreat Dis Int, 15, pp.371~377 (2016)
  51. Park WH, "Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization", J Vasc Interv Radiol, 23, pp.927~936 (2012)
  52. Yang S, "Usefulness of serum PIVKA-II as a marker of radiological response and survival outcome in patients with hepatocellular carcinoma undergoing transarterial chemoembolization", Hepatol Int, 14(Suppl 1), pp.S258~ (2020)
  53. Yang M, "Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy : a systematic review and meta-analysis", PLoS One, 14, pp.e0225170~ (2019)
  54. Arai T, "Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization", Int J Clin Oncol, 19, pp.871~879 (2014)
  55. Lim TS, "Alphafetoprotein, des-gamma-carboxy prothrombin, and modified RECIST response as predictors of survival after transarterial radioembolization for hepatocellular carcinoma", J Vasc Interv Radiol, 30, pp.1194~1200 (2019)
  56. Lai Q, "Des-gamma-carboxy prothrombin in hepatocellular cancer patients waiting for liver transplant : a systematic review and meta-analysis", Int J Biol Markers, 32, pp.e370~e374 (2017)
  57. Lee HW, "Patient selection by tumor markers in liver transplantation for advanced hepatocellular carcinoma", Liver Transpl, 24, pp.1243~1251 (2018)
  58. Todo S, "Extending indication : role of living donor liver transplantation for hepatocellular carcinoma", Liver Transpl, 13(11 Suppl 2), pp.S48~S54 (2007)
  59. "Combating hepatitis B and C to reach elimination by 2030 - Advocacy brief"[URL]
  60. Qian X, "Reappraisal of the diagnostic value of alpha-fetoprotein for surveillance of HBV-related hepatocellular carcinoma in the era of antiviral therapy", J Viral Hepat, 28, pp.20~29 (2021)
  61. Wong GL, "Ontreatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir", Hepatology, 59, pp.986~995 (2014)
  62. Basile U, "The diagnostic performance of PIVKA-II in metabolic and viral hepatocellular carcinoma : a pilot study", Eur Rev Med Pharmacol Sci, 24, pp.12675~12685 (2020)
  63. Sumida Y, "Surveillance of hepatocellular carcinoma in nonalcoholic fatty liver disease", Diagnostics(Basel), 10, pp.579~ (2020)

관련 논문AI추천

간세포암의 진단과 치료에서 종양표지자의 역할장영, 장재영대한내과학회 · 대한내과학회지2020 · 제95권 제1호간세포암의 진단과 재발판정에서 PIVKA-II의 유용성김경규, 김도영, 김자경, 문영명, 백용한, 심명기, 안상훈, 이관식, 전재윤, 한광협대한내과학회 · 대한내과학회지2005 · 제69권 제1호간세포암종 진단에 유의한 PIVKA-II 값의 제시 - ROC Curve를 이용하여 -김동우, 김명진, 김정혁, 방기태, 배강우, 서평주, 송일한, 이보한, 정인국대한간학회 · Clinical and Molecular Hepatology2006 · 제12권 제3호간세포암종의 진단 및 치료 후 추적 관찰에서 혈청 PIVKA-II의 임상적 효용성김철, 김용수, 김현숙, 문영명, 윤영준, 전재윤, 최혜진, 한광협, 한재용, 한창훈대한간학회 · Clinical and Molecular Hepatology2002 · 제8권 제2002호Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?Amit G. Singal, Ibrahim A. Hanouneh, Naim Alkhouri대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제3호Feasibility of α-fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea강현, 배시현, 이준성, 이현웅, Dae Geon Ahn, Hyung Joon Kim, Joon Hyoek Lee, Yong Han Paik대한내과학회 · The Korean Journal of Internal Medicine2016 · 제31권 제1호

이 간행물의 다른 논문 (53건)

Congratulatory remarksSi Hyun Baepp. 1-1Special thanksSeung Up Kimpp. 4-4MAFLD: How is it different from NAFLD?Ming-Hua Zheng, Jacob George, Cameron Gofton, Yadhavan Upendranpp. 17-31Global incidence and prevalence of nonalcoholic fatty liver diseaseEunice Tan, Mark D. Muthiah, Cheng Han Ng, Margaret LP Teng, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Daniel Q. Huangpp. 32-42Nonalcoholic fatty liver disease and non-liver comorbiditiesRichie Manikat, Mindie H. Nguyenpp. 86-102
원문 보기